Na Julaị 5, Novo Nordisk bidoro nnwale ụlọ ọgwụ nke Atọ nke CagriSema na China, ebumnuche ya bụ iji nchekwa na arụmọrụ nke injection CagriSema na semeglutide na ndị ọrịa buru ibu na oke ibu na China.
Ngwunye CagriSema bụ ọgwụgwọ ngwakọta na-eme ogologo oge n'okpuru mmepe nke Novo Nordisk, ihe ndị bụ isi bụ GLP-1 (glucagon-like peptide-1) agonist smeglutide na-anabata ya na amylin analog cagrilintide na-eme ogologo oge.Enwere ike ịgba ọgwụ mgbochi CagriSema n'okpuru akpụkpọ ahụ otu ugboro n'izu.
Ebumnuche bụ isi bụ iji CagriSema (2.4 mg/2.4 mg) tụnyere semeglutide ma ọ bụ placebo otu ugboro kwa izu n'okpuru akpụkpọ ahụ.Novo Nordisk ekwupụtala nsonaazụ nke nnwale CagriSema maka ọgwụgwọ ọrịa shuga 2, nke gosipụtara na mmetụta hypoglycemic nke CagriSema dị mma karịa nke semeglutide, ihe fọrọ nke nta ka ọ bụrụ 90% nke isiokwu enwetala ebumnuche HbA1c.
Ihe omuma a gosiputara na na mgbakwunye na mmetụta hypoglycemic dị ịrịba ama, n'ihe gbasara oke ibu, injection CagriSema pụtara nke ọma semeglutide (5.1%) na cagrilintide (8.1%) na mbelata nke 15.6%.
Ọgwụ ọhụrụ Tirzepatide bụ agonist nnabata GIP/GLP-1 nke izizi na-enweta kwa izu n'ụwa.Ọ na-ejikọta mmetụta nke incretins abụọ n'ime otu molecule nke a na-agbanye otu ugboro n'izu ma bụrụ klas ọhụrụ nke ọgwụgwọ maka ụdị ọrịa shuga 2.Ndị US Food and Drug Administration (FDA) kwadoro Tirzepatide na Mee 2022 iji melite njikwa glycemic (na nri nri na mmega ahụ) na ndị okenye nwere ụdị ọrịa shuga 2 ma kwadoro ugbu a na European Union, Japan na mba ndị ọzọ.
Na Julaị 5, Eli Lilly kwupụtara usoro ọmụmụ nke III SURPASS-CN-MONO na ndebanye aha ụlọ ọgwụ ọgwụ yana ikpo okwu ngosi maka ọgwụgwọ ndị ọrịa shuga 2.SURPASS-CN-MONO bụ usoro ọmụmụ nke usoro III nke a na-achịkwaghị achịkwa, nke kpuru ìsì abụọ, nke e mere iji nyochaa ịdị irè na nchekwa nke tirzepatide monotherapy ma e jiri ya tụnyere placebo na ndị nwere ụdị ọrịa shuga 2.Ọmụmụ ihe ahụ mere atụmatụ ịgụnye ndị ọrịa 200 nwere ụdị ọrịa shuga 2 ndị na-anọghị na ọgwụ antidiabetic ọ bụla n'ime ụbọchị 90 tupu nleta 1 (ma e wezụga n'ọnọdụ ụfọdụ ụlọ ọgwụ, dị ka ọrịa siri ike, ụlọ ọgwụ, ma ọ bụ ịwa ahụ ahọpụtara, obere oge (≤14). ụbọchị) iji insulin).
A na-atụ anya ịkwado ụdị ọrịa shuga 2 nke afọ a
N'ọnwa gara aga, e bipụtara nsonaazụ SURPASS-AP-Combo na Mee 25 na akwụkwọ akụkọ blockbuster Nature Medicine.Nsonaazụ gosiri na ma e jiri ya tụnyere insulin glargine, Tirzepatide gosipụtara HbA1c ka mma yana mbelata ịdị arọ nke ndị ọrịa nwere ụdị ọrịa shuga 2 na mpaghara Asia-Pacific (karịsịa China): Mbelata HbA1c ruru 2.49% yana mbelata ịdị arọ ruru 7.2 kg. (9.4%) na 40 izu ọgwụgwọ, mmụba dị ịrịba ama na lipids ọbara na ọbara mgbali elu, na nchekwa zuru oke na nnabata dị mma.
Nnwale ụlọ ọgwụ nke Phase 3 nke SURPASS-AP-Combo bụ nyocha izizi Tirzepatide mere na ndị ọrịa China nwere ụdị ọrịa shuga 2, nke Prọfesọ Ji Linong nke ụlọ ọgwụ ndị mmadụ na Mahadum Peking duziri.SURPASS-AP-Combo kwekọrọ na nsonaazụ nke usoro nyocha nke SURPASS zuru ụwa ọnụ, nke na-egosipụtakwa na pathophysiology nke ọrịa shuga na ndị ọrịa China kwekọrọ na nke ndị ọrịa ụwa niile, nke bụ ntọala maka nyocha n'otu oge na mmepe nke ọgwụ ọhụrụ. na China na ụwa, ma na-enyekwa nkwado nkwado siri ike maka inye ndị ọrịa China ohere iji ọgwụ ọgwụgwọ ọrịa shuga kachasị ọhụrụ na ngwa ụlọ ọgwụ ha na China ozugbo enwere ike.
Oge nzipu: Sep-18-2023